BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neldaleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Neldaleucel\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05798897-10972@assetmemo.bio
DTSTAMP:20261121T005328Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Neldaleucel: Phase 1 readout est. (NCT05798897)
DESCRIPTION:Neldaleucel\, phase 1\, Relapsed/Refractory Non-Hodgkin Lymphom
 a.\nStudy: Safety and Preliminary Efficacy of MT-601 in Patients With Rela
 psed/Refractory Lymphoma\nEstimated primary completion: 28 February 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/neldaleucel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05798897
URL:https://assetmemo.bio/drug/neldaleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549751-10972@assetmemo.bio
DTSTAMP:20261121T005328Z
DTSTART;VALUE=DATE:20280716
DTEND;VALUE=DATE:20280717
SUMMARY:Neldaleucel: Phase 1 readout est. (NCT06549751)
DESCRIPTION:Neldaleucel\, phase 1.\nStudy: MT-601 Administered To Patients 
 With Locally Advanced Unresectable or Metastatic Pancreatic Cancer\nEstima
 ted primary completion: 16 July 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/neldaleucel#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06549751
URL:https://assetmemo.bio/drug/neldaleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
